Curated News
By: NewsRamp Editorial Staff
May 29, 2024
hyperCORE International Welcomes ARC to Clinical Trial Network
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- ARC's collaboration with hyperCORE provides access to a super network for conducting groundbreaking clinical trials, giving them a competitive advantage in the industry.
- hyperCORE International is a network of clinical research site companies that streamlines business and clinical operations through harmonization, providing Phase I-IV clinical trial services.
- By joining hyperCORE, ARC aims to make significant advancements in the clinical research industry, impacting the community and fostering empathy and understanding in patient care.
- Dr. Nathan Livers, CEO of ARC, is a double-board-certified physician with a clinical emphasis on OBGYN and obesity management, offering a wide range of services to address diverse patient needs.
Impact - Why it Matters
The inclusion of ARC into hyperCORE's network signifies an expansion of clinical trial capabilities and global reach, potentially leading to groundbreaking advancements in pharmaceutical, medical, and device trials. Dr. Livers' emphasis on patient care and clinical research also indicates a positive impact on the community and potential improvements in healthcare outcomes. Overall, this news highlights the importance of collaboration in advancing clinical research and improving patient care.
Summary
hyperCORE International has welcomed Applied Research Center of Arkansas to its clinical trial network, expanding its global reach. ARC is a multi-specialty research organization in Little Rock, conducting Phase I - IV pharmaceutical, medical, and device trials, led by CEO Dr. Nathan Livers. Dr. Livers, a double-board-certified physician, is driven by a passion for clinical research and patient care, making the decision to join hyperCORE an easy one.
Source Statement
This curated news summary relied on this press release disributed by 24-7 Press Release. Read the source press release here, hyperCORE International Welcomes ARC to Clinical Trial Network
